Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Acquires $174,146.00 in Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy bought 88,850 shares of the stock in a transaction dated Tuesday, November 26th. The shares were bought at an average cost of $1.96 per share, with a total value of $174,146.00. Following the completion of the acquisition, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. The trade was a 8.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Pyxis Oncology Stock Performance

Shares of PYXS stock traded up $0.06 during midday trading on Wednesday, reaching $1.83. 1,809,338 shares of the company were exchanged, compared to its average volume of 753,874. Pyxis Oncology, Inc. has a 12 month low of $1.48 and a 12 month high of $6.85. The company has a market cap of $108.83 million, a P/E ratio of -1.78 and a beta of 1.27. The company’s 50 day moving average price is $3.54 and its two-hundred day moving average price is $3.56.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fullcircle Wealth LLC bought a new stake in shares of Pyxis Oncology during the 2nd quarter worth about $40,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology in the 1st quarter worth approximately $59,000. Intech Investment Management LLC bought a new stake in shares of Pyxis Oncology in the 3rd quarter worth approximately $55,000. MetLife Investment Management LLC raised its holdings in shares of Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Pyxis Oncology in the 2nd quarter worth approximately $65,000. 39.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PYXS has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, November 21st. Stifel Nicolaus started coverage on shares of Pyxis Oncology in a report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target for the company. Royal Bank of Canada upped their price target on shares of Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Finally, Stephens initiated coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Pyxis Oncology has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.